HCA Healthcare (HCA)
HCA Healthcare on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on NYSE, classified by the SEC as services-general medical & surgical hospitals, nec.
4.9M
Short interest
settlement 2026-10-15
4.6
Days to cover
+1.5 days vs prior
38.2%
Short share of volume
2026-10-28
491
Fails to deliver
settlement 2026-09-24
Tue 26 Jan
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-10-28.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in HCA is 4,906,014 shares, down 1,573,971 shares over the last month. Over the last 48 readings it ranged from 2,595,877 shares (31 October 2024) to 6,479,985 shares (15 September 2026). At the reported average volume of 1.1M shares a day that is 4.6 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/hca" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 4,906,014 | +0.4% | 1,065,948 | 4.60 |
| 2026-09-30 | 4,884,718 | -24.6% | 1,594,337 | 3.06 |
| 2026-09-15 | 6,479,985 | +5.6% | 1,433,168 | 4.52 |
| 2026-08-31 | 6,135,558 | +0.1% | 1,248,041 | 4.92 |
| 2026-08-14 | 6,127,018 | +1.1% | 1,102,584 | 5.56 |
| 2026-07-31 | 6,058,463 | +4.0% | 1,717,800 | 3.53 |
| 2026-07-15 | 5,826,249 | +8.8% | 1,864,076 | 3.13 |
| 2026-06-30 | 5,354,923 | +2.7% | 1,540,993 | 3.47 |
| 2026-06-15 | 5,214,285 | +0.0% | 1,931,748 | 2.70 |
| 2026-05-29 | 5,214,258 | +17.1% | 1,758,543 | 2.97 |
| 2026-05-15 | 4,454,149 | +2.9% | 1,225,076 | 3.64 |
| 2026-04-30 | 4,330,447 | +9.3% | 1,323,991 | 3.27 |
| 2026-04-15 | 3,963,348 | +9.3% | 825,888 | 4.80 |
| 2026-03-31 | 3,625,761 | +8.5% | 1,124,935 | 3.22 |
| 2026-03-13 | 3,342,178 | -5.7% | 1,014,821 | 3.29 |
| 2026-02-27 | 3,542,414 | -9.7% | 1,168,164 | 3.03 |
| 2026-02-13 | 3,924,877 | -5.1% | 1,175,604 | 3.34 |
| 2026-01-30 | 4,135,586 | +5.4% | 1,349,524 | 3.06 |
| 2026-01-15 | 3,922,164 | -4.9% | 948,768 | 4.13 |
| 2025-12-31 | 4,124,926 | -8.2% | 1,172,083 | 3.52 |
| 2025-12-15 | 4,495,103 | -8.8% | 1,320,832 | 3.40 |
| 2025-11-28 | 4,928,210 | +8.6% | 1,403,063 | 3.51 |
| 2025-11-14 | 4,536,300 | +12.9% | 1,261,037 | 3.60 |
| 2025-10-31 | 4,019,017 | +23.2% | 1,514,379 | 2.65 |
| 2025-10-15 | 3,263,233 | -8.4% | 1,241,661 | 2.63 |
| 2025-09-30 | 3,561,967 | -15.8% | 1,395,085 | 2.55 |
| 2025-09-15 | 4,228,281 | -1.0% | 1,190,700 | 3.55 |
| 2025-08-29 | 4,270,707 | +3.6% | 1,108,755 | 3.85 |
| 2025-08-15 | 4,123,693 | +1.5% | 1,135,755 | 3.63 |
| 2025-07-31 | 4,061,766 | +4.4% | 1,900,984 | 2.14 |
| 2025-07-15 | 3,888,909 | +4.1% | 1,192,802 | 3.26 |
| 2025-06-30 | 3,736,998 | -19.4% | 1,714,952 | 2.18 |
| 2025-06-13 | 4,638,449 | +4.0% | 1,152,578 | 4.02 |
| 2025-05-30 | 4,458,002 | -11.4% | 1,462,333 | 3.05 |
| 2025-05-15 | 5,029,582 | +13.4% | 1,567,700 | 3.21 |
| 2025-04-30 | 4,433,164 | -6.6% | 1,686,220 | 2.63 |
| 2025-04-15 | 4,744,778 | -14.9% | 1,809,526 | 2.62 |
| 2025-03-31 | 5,576,020 | +12.9% | 1,490,930 | 3.74 |
| 2025-03-14 | 4,939,866 | -16.1% | 1,570,787 | 3.14 |
| 2025-02-28 | 5,891,356 | -2.4% | 1,974,624 | 2.98 |
| 2025-02-14 | 6,038,138 | +13.4% | 1,554,729 | 3.88 |
| 2025-01-31 | 5,325,076 | +11.6% | 1,913,491 | 2.78 |
| 2025-01-15 | 4,769,703 | +8.4% | 1,499,905 | 3.18 |
| 2024-12-31 | 4,401,009 | -7.8% | 1,315,473 | 3.35 |
| 2024-12-13 | 4,775,368 | +35.4% | 1,303,966 | 3.66 |
| 2024-11-29 | 3,526,275 | +18.6% | 1,529,360 | 2.31 |
| 2024-11-15 | 2,972,182 | +14.5% | 1,608,283 | 1.85 |
| 2024-10-31 | 2,595,877 | -9.2% | 1,614,178 | 1.61 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 28 October 2026, the short share of HCA volume is 38.2%, down 31.3 points over the last five sessions. Over the last 30 readings it ranged from 38.2% (28 October 2026) to 77.3% (23 October 2026). The latest reading sits at the bottom of that range. The latest reading is 21.3 points below the 30-session average of 59.5%, on 777K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-28 | 297K | 777K | 38.2% | 3,151 |
| 2026-10-27 | 736K | 1.2M | 60.3% | 0 |
| 2026-10-26 | 478K | 710K | 67.3% | 15 |
| 2026-10-23 | 294K | 381K | 77.3% | 475 |
| 2026-10-22 | 163K | 323K | 50.4% | 373 |
| 2026-10-21 | 176K | 253K | 69.5% | 250 |
| 2026-10-20 | 372K | 507K | 73.5% | 35 |
| 2026-10-19 | 218K | 327K | 66.7% | 952 |
| 2026-10-16 | 267K | 501K | 53.3% | 15 |
| 2026-10-15 | 193K | 419K | 46.0% | 65 |
| 2026-10-14 | 198K | 340K | 58.3% | 9 |
| 2026-10-13 | 202K | 415K | 48.8% | 556 |
| 2026-10-12 | 219K | 439K | 49.9% | 380 |
| 2026-10-09 | 233K | 361K | 64.5% | 82 |
| 2026-10-08 | 220K | 357K | 61.7% | 0 |
| 2026-10-07 | 182K | 296K | 61.3% | 2 |
| 2026-10-06 | 238K | 347K | 68.5% | 5 |
| 2026-10-05 | 189K | 306K | 61.8% | 66 |
| 2026-10-02 | 187K | 265K | 70.5% | 102 |
| 2026-10-01 | 235K | 352K | 66.7% | 121 |
| 2026-09-30 | 190K | 361K | 52.7% | 181 |
| 2026-09-29 | 137K | 307K | 44.7% | 0 |
| 2026-09-28 | 155K | 309K | 50.0% | 1,069 |
| 2026-09-25 | 191K | 334K | 57.0% | 160 |
| 2026-09-24 | 214K | 320K | 66.8% | 45 |
| 2026-09-23 | 233K | 417K | 55.8% | 0 |
| 2026-09-22 | 192K | 404K | 47.4% | 0 |
| 2026-09-21 | 205K | 397K | 51.7% | 400 |
| 2026-09-18 | 372K | 516K | 72.0% | 0 |
| 2026-09-17 | 292K | 408K | 71.5% | 4 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 24 September 2026, the fails-to-deliver balance in HCA is 491 shares, up 143 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (23 April 2026) to 104,600 shares (26 August 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-24 | 491 | $436.48 | $214K |
| 2026-09-21 | 348 | $427.71 | $149K |
| 2026-09-17 | 25 | $430.43 | $11K |
| 2026-08-26 | 104,600 | $428.76 | $44.8M |
| 2026-08-24 | 100 | $429.19 | $43K |
| 2026-08-19 | 1,175 | $411.73 | $484K |
| 2026-08-18 | 20,525 | $404.98 | $8.3M |
| 2026-08-17 | 22,136 | $404.68 | $9.0M |
| 2026-08-13 | 61,608 | $414.59 | $25.5M |
| 2026-08-11 | 79 | $414.03 | $33K |
| 2026-08-07 | 74 | $408.89 | $30K |
| 2026-08-03 | 69 | $402.59 | $28K |
| 2026-07-23 | 77 | $371.87 | $29K |
| 2026-07-01 | 6 | $389.89 | $2K |
| 2026-06-29 | 2 | $391.68 | $783 |
| 2026-06-25 | 4,808 | $387.76 | $1.9M |
| 2026-06-17 | 44 | $396.93 | $17K |
| 2026-06-15 | 1,179 | $387.18 | $456K |
| 2026-06-08 | 2,349 | $372.13 | $874K |
| 2026-05-26 | 328 | $394.07 | $129K |
| 2026-05-20 | 5,765 | $404.69 | $2.3M |
| 2026-04-24 | 25 | $474.03 | $12K |
| 2026-04-23 | 1 | $471.34 | $471 |
| 2026-04-17 | 361 | $482.97 | $174K |
| 2026-04-16 | 310 | $488.58 | $151K |
| 2026-04-08 | 2,569 | $489.58 | $1.3M |
| 2026-03-25 | 15 | $485.72 | $7K |
| 2026-03-23 | 18 | $493.88 | $9K |
| 2026-03-11 | 13 | $537.64 | $7K |
| 2026-03-10 | 4,807 | $545.13 | $2.6M |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for HCA in the last 90 days. The most recent filings are listed below. Latest filing: McAlevey Michael R (EVP & Chief Legal & Admin Off.) on 2026-08-26.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-08-26 | McAlevey Michael R | EVP & Chief Legal & Admin Off. | Other transaction | 8K | $429.00 | $3.3M | 0 |
| 2026-05-07 | Marks Mike A | EVP and CFO | Gift | 3K | $0.00 | $0 | 47K |
| 2026-05-07 | Marks Mike A | EVP and CFO | Gift | 3K | $0.00 | $0 | 0 |
| 2026-04-28 | Smith Andrea B | Director | Grant | 509 | $0.00 | $0 | 5K |
| 2026-04-28 | Riley Wayne Joseph | Director | Grant | 509 | $0.00 | $0 | 15K |
| 2026-04-28 | MICHELSON MICHAEL W | Director | Grant | 925 | $0.00 | $0 | 13K |
| 2026-04-28 | Johnston Hugh F | Director | Grant | 809 | $0.00 | $0 | 4K |
| 2026-04-28 | Frist William R | Director, 10% owner | Grant | 809 | $0.00 | $0 | 14K |
| 2026-04-28 | FRIST THOMAS F III | Director, 10% owner | Grant | 1K | $0.00 | $0 | 16K |
| 2026-04-28 | DEPARLE NANCY ANN | Director | Grant | 509 | $0.00 | $0 | 22K |
| 2026-04-28 | CHIDSEY JOHN | Director | Grant | 809 | $0.00 | $0 | 1K |
| 2026-02-18 | McAlevey Michael R | EVP & Chief Legal & Admin Off. | Sell | 2K | $533.37 | $904K | 9K |
| 2026-02-13 | McAlevey Michael R | EVP & Chief Legal & Admin Off. | Tax withholding | 3K | $540.29 | $1.8M | 11K |
| 2026-02-13 | McAlevey Michael R | EVP & Chief Legal & Admin Off. | Exercise or conversion | 5K | $236.61 | $1.2M | 14K |
| 2026-02-11 | Berres Jennifer | SVP & Chief Human Res. Officer | Sell | 4K | $526.16 | $2.1M | 12K |
| 2026-02-11 | Wyatt Christopher F. | SVP & Controller | Sell | 4K | $505.00 | $2.0M | 44K |
| 2026-02-11 | Berres Jennifer | SVP & Chief Human Res. Officer | Sell | 4K | $503.00 | $2.0M | 16K |
| 2026-02-10 | Wyatt Christopher F. | SVP & Controller | Tax withholding | 1K | $502.05 | $519K | 48K |
| 2026-02-10 | Wyatt Christopher F. | SVP & Controller | Grant | 3K | $0.00 | $0 | 49K |
| 2026-02-10 | Rossitto Erica | SVP & Chief Nurse Executive | Tax withholding | 418 | $502.05 | $210K | 10K |
| 2026-02-10 | Rossitto Erica | SVP & Chief Nurse Executive | Grant | 2K | $0.00 | $0 | 11K |
| 2026-02-10 | McAlevey Michael R | EVP & Chief Legal & Admin Off. | Tax withholding | 3K | $502.05 | $1.5M | 9K |
| 2026-02-10 | McAlevey Michael R | EVP & Chief Legal & Admin Off. | Grant | 8K | $0.00 | $0 | 12K |
| 2026-02-10 | Marks Mike A | EVP and CFO | Tax withholding | 2K | $502.05 | $848K | 3K |
| 2026-02-10 | Marks Mike A | EVP and CFO | Grant | 5K | $0.00 | $0 | 5K |
| 2026-02-10 | HAZEN SAMUEL N | CEO | Tax withholding | 21K | $502.05 | $10.7M | 65K |
| 2026-02-10 | HAZEN SAMUEL N | CEO | Grant | 55K | $0.00 | $0 | 86K |
| 2026-02-10 | Foster Jon M | EVP and COO | Tax withholding | 6K | $502.05 | $3.0M | 23K |
| 2026-02-10 | Foster Jon M | EVP and COO | Grant | 16K | $0.00 | $0 | 29K |
| 2026-02-10 | Cuffe Michael S. | EVP and Chief Clinical Officer | Tax withholding | 4K | $502.05 | $1.8M | 32K |
| 2026-02-10 | Cuffe Michael S. | EVP and Chief Clinical Officer | Grant | 10K | $0.00 | $0 | 36K |
| 2026-02-10 | Berres Jennifer | SVP & Chief Human Res. Officer | Tax withholding | 3K | $502.05 | $1.3M | 20K |
| 2026-02-10 | Berres Jennifer | SVP & Chief Human Res. Officer | Grant | 7K | $0.00 | $0 | 23K |
| 2026-02-06 | Frisco Holding II | TenPercentOwner | Other transaction | 36.6M | price not stated in the filing | not stated | 36.6M |
| 2026-02-06 | Frisco Holding II | TenPercentOwner | Other transaction | 36.6M | price not stated in the filing | not stated | 0 |
| 2026-02-06 | Elcan Patricia F | TenPercentOwner | Other transaction | 36.6M | price not stated in the filing | not stated | 0 |
| 2026-02-06 | Elcan Patricia F | TenPercentOwner | Other transaction | 36.6M | price not stated in the filing | not stated | 36.6M |
| 2026-02-06 | FRIST THOMAS F III | Director,TenPercentOwner | Other transaction | 36.6M | price not stated in the filing | not stated | 36.6M |
| 2026-02-06 | FRIST THOMAS F III | Director,TenPercentOwner | Other transaction | 36.6M | price not stated in the filing | not stated | 0 |
| 2026-02-06 | Frist William R | Director,TenPercentOwner | Other transaction | 36.6M | price not stated in the filing | not stated | 36.6M |
| 2026-02-06 | Frist William R | Director,TenPercentOwner | Other transaction | 36.6M | price not stated in the filing | not stated | 0 |
| 2026-02-06 | FRIST THOMAS F JR | TenPercentOwner | Other transaction | 36.6M | price not stated in the filing | not stated | 0 |
| 2026-02-06 | FRIST THOMAS F JR | TenPercentOwner | Other transaction | 36.6M | price not stated in the filing | not stated | 36.6M |
| 2026-02-06 | HERCULES HOLDING II | 10% owner | Other transaction | 36.6M | $0.00 | $0 | 32.3M |
| 2026-02-05 | Wyatt Christopher F. | SVP & Controller | Tax withholding | 6K | $513.76 | $2.9M | 46K |
| 2026-02-05 | Wyatt Christopher F. | SVP & Controller | Exercise or conversion | 11K | $139.06 | $1.5M | 52K |
| 2026-02-05 | Foster Jon M | EVP and COO | Tax withholding | 16K | $513.76 | $8.3M | 13K |
| 2026-02-05 | Foster Jon M | EVP and COO | Exercise or conversion | 29K | $139.06 | $4.1M | 29K |
| 2026-02-04 | HAZEN SAMUEL N | CEO | Other transaction | 1K | $498.35 | $521K | 16K |
| 2026-02-04 | HAZEN SAMUEL N | CEO | Other transaction | 1K | $498.35 | $521K | 31K |
| 2026-02-03 | HAZEN SAMUEL N | CEO | Sell | 120 | $497.18 | $60K | 32K |
| 2026-02-03 | HAZEN SAMUEL N | CEO | Sell | 4K | $498.12 | $2.1M | 32K |
| 2026-02-03 | HAZEN SAMUEL N | CEO | Sell | 5K | $498.80 | $2.6M | 37K |
| 2026-02-03 | HAZEN SAMUEL N | CEO | Sell | 6K | $500.02 | $3.1M | 42K |
| 2026-02-03 | HAZEN SAMUEL N | CEO | Sell | 7K | $500.69 | $3.7M | 48K |
| 2026-02-03 | HAZEN SAMUEL N | CEO | Sell | 5K | $502.15 | $2.5M | 55K |
| 2026-02-03 | HAZEN SAMUEL N | CEO | Sell | 15K | $502.95 | $7.4M | 60K |
| 2026-02-03 | Cuffe Michael S. | EVP and Chief Clinical Officer | Gift | 4K | $0.00 | $0 | 26K |
| 2026-02-03 | Cuffe Michael S. | EVP and Chief Clinical Officer | Sell | 2K | $498.09 | $747K | 30K |
| 2026-01-30 | HAZEN SAMUEL N | CEO | Tax withholding | 41K | $488.27 | $20.3M | 75K |
| 2026-01-30 | HAZEN SAMUEL N | CEO | Exercise or conversion | 84K | $81.96 | $6.9M | 117K |
| 2025-11-14 | HAZEN SAMUEL N | CEO | Gift | 15K | $0.00 | $0 | 32K |
| 2025-11-05 | McAlevey Michael R | EVP & Chief Legal & Admin Off. | Sell | 4K | $473.79 | $1.8M | 3K |
| 2025-11-05 | Marks Mike A | EVP and CFO | Gift | 165 | $0.00 | $0 | 0 |
| 2025-11-03 | Marks Mike A | EVP and CFO | Gift | 165 | $0.00 | $0 | 165 |
| 2025-11-03 | McAlevey Michael R | EVP & Chief Legal & Admin Off. | Tax withholding | 9K | $461.56 | $4.3M | 7K |
| 2025-11-03 | McAlevey Michael R | EVP & Chief Legal & Admin Off. | Exercise or conversion | 13K | $236.61 | $3.1M | 17K |
| 2025-11-03 | Marks Mike A | EVP and CFO | Gift | 165 | $0.00 | $0 | 43K |
| 2025-10-31 | HAZEN SAMUEL N | CEO | Tax withholding | 28K | $459.68 | $13.0M | 47K |
| 2025-10-31 | HAZEN SAMUEL N | CEO | Exercise or conversion | 58K | $69.58 | $4.0M | 75K |
| 2025-09-08 | Cuffe Michael S. | EVP and Chief Clinical Officer | Sell | 4K | $418.84 | $1.6M | 32K |
| 2025-09-04 | Cuffe Michael S. | EVP and Chief Clinical Officer | Tax withholding | 7K | $411.59 | $2.9M | 35K |
| 2025-09-04 | Cuffe Michael S. | EVP and Chief Clinical Officer | Exercise or conversion | 11K | $173.12 | $1.9M | 42K |
| 2025-07-29 | CHIDSEY JOHN | Director | Grant | 496 | $0.00 | $0 | 496 |
| 2025-05-13 | HAZEN SAMUEL N | CEO | Gift | 90K | $0.00 | $0 | 0 |
| 2025-05-13 | Foster Jon M | EVP and COO | Other transaction | 16K | $367.19 | $5.8M | 72K |
| 2025-05-13 | Foster Jon M | EVP and COO | Gift | 2K | $0.00 | $0 | 16K |
| 2025-05-13 | Foster Jon M | EVP and COO | Gift | 1K | $0.00 | $0 | 12K |
| 2025-05-13 | Foster Jon M | EVP and COO | Sell | 16K | $369.32 | $5.8M | 13K |
| 2025-05-13 | Foster Jon M | EVP and COO | Gift | 1K | $0.00 | $0 | 68K |
| 2025-05-13 | Foster Jon M | EVP and COO | Other transaction | 16K | $367.20 | $5.8M | 0 |
| 2025-05-13 | Foster Jon M | EVP and COO | Gift | 2K | $0.00 | $0 | 56K |
| 2025-05-13 | HAZEN SAMUEL N | CEO | Gift | 90K | $0.00 | $0 | 93K |
| 2025-05-07 | Marks Mike A | EVP and CFO | Other transaction | 285 | $356.84 | $102K | 0 |
| 2025-05-07 | Marks Mike A | EVP and CFO | Gift | 181 | $0.00 | $0 | 285 |
| 2025-05-07 | Marks Mike A | EVP and CFO | Other transaction | 285 | $356.84 | $102K | 43K |
| 2025-05-07 | Marks Mike A | EVP and CFO | Gift | 144 | $0.00 | $0 | 0 |
| 2025-05-07 | Marks Mike A | EVP and CFO | Gift | 181 | $0.00 | $0 | 43K |
| 2025-05-06 | Marks Mike A | EVP and CFO | Other transaction | 288 | $353.57 | $102K | 43K |
| 2025-05-06 | Marks Mike A | EVP and CFO | Gift | 466 | $0.00 | $0 | 0 |
| 2025-05-06 | Marks Mike A | EVP and CFO | Gift | 466 | $0.00 | $0 | 466 |
| 2025-05-06 | Marks Mike A | EVP and CFO | Other transaction | 288 | $353.58 | $102K | 288 |
| 2025-05-06 | Marks Mike A | EVP and CFO | Gift | 144 | $0.00 | $0 | 144 |
| 2025-04-30 | Frist William R | Director,TenPercentOwner | Other transaction | 11K | $340.60 | $3.6M | 1.6M |
| 2025-04-29 | Dennis Robert J | Director | Grant | 1K | $0.00 | $0 | 27K |
| 2025-04-29 | DEPARLE NANCY ANN | Director | Grant | 645 | $0.00 | $0 | 21K |
| 2025-04-29 | Johnston Hugh F | Director | Grant | 1K | $0.00 | $0 | 4K |
| 2025-04-29 | MICHELSON MICHAEL W | Director | Grant | 1K | $0.00 | $0 | 12K |
| 2025-04-29 | Riley Wayne Joseph | Director | Grant | 645 | $0.00 | $0 | 15K |
| 2025-04-29 | Smith Andrea B | Director | Grant | 645 | $0.00 | $0 | 4K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON5 Form 144 notices on file for HCA worth $29.1M at the prices reported; 0 in the last 90 days worth $0. Latest: Michael R McAlevey filed on 2026-02-18 to sell 1,694 shares ($903K) from 2026-02-18.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-02-18 | Michael R McAleveyOFFICER | 2K | $903K | 0.001% | 2026-02-18 | Merrill Lynch |
| 2026-02-11 | Jennifer L. BerresOFFICER | 8K | $4.1M | 0.004% | 2026-02-11 | Merrill Lynch |
| 2026-02-03 | Samuel N. HazenPresident, Chief Executive Officer & Director | 43K | $21.5M | 0.019% | 2026-02-03 | Merrill Lynch |
| 2026-02-03 | MICHAEL S CUFFEOFFICER | 2K | $747K | 0.001% | 2026-02-03 | Merrill Lynch |
| 2025-11-05 | Michael R McAleveyOFFICER | 4K | $1.8M | 0.002% | 2025-11-05 | Merrill Lynch |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON7 holders report 5% or more of HCA in their latest filing, 6 on Schedule 13D (active intent). The largest reported stake is Thomas F. Frist, Jr. at 31.6% of the class (70,555,590 shares), filed 2026-02-10 for an event on 2026-02-06.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-04-30 | 13G | Vanguard Capital Managementinvestment adviser | 11.7M | 5.3% | 2026-03-31 |
| 2026-03-27 | 13G/Ano. 8 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-02-10 | 13D | Thomas F. Frist, Jr.individual | 70.6M | 31.6% | 2026-02-06 |
| 2026-02-10 | 13D | William R. Fristindividual | 70.5M | 31.5% | 2026-02-06 |
| 2026-02-10 | 13D | Patricia F. Elcanindividual | 70.2M | 31.4% | 2026-02-06 |
| 2026-02-10 | 13D | Thomas F. Frist IIIindividual | 70.0M | 31.3% | 2026-02-06 |
| 2026-02-10 | 13D | Frisco Holding IIpartnership | 38.9M | 17.4% | 2026-02-06 |
| 2026-02-10 | 13D | Hercules Holding IIpartnership | 34.6M | 15.5% | 2026-02-06 |
13F holders
Tracked managers holding HCA at their latest 13F. JSON7 of the 30 tracked managers held HCA at their latest 13F, $326.5M in total at quarter-end prices. AQR Capital Management is the largest at $87.6M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 5 added shares and 2 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| AQR Capital Management | 2026-06-30 | 225K | $87.6M | 0.03% | -105K |
| Bridgewater Associates | 2026-06-30 | 203K | $79.2M | 0.33% | +29K |
| Citadel Advisors | 2026-06-30 | 184K | $71.9M | 0.01% | -74K |
| D. E. Shaw & Co. | 2026-06-30 | 139K | $54.4M | 0.03% | +90K |
| Millennium Management | 2026-06-30 | 64K | $24.9M | 0.01% | +50K |
| Renaissance Technologies | 2026-06-30 | 19K | $7.3M | 0.01% | new |
| Fisher Asset Management | 2026-06-30 | 3K | $1.2M | 0.00% | +1K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q1 FY 2026 (quarter ended 2026-03-31) HCA Healthcare reported revenue of $19.11B, up 4.3% from the same quarter a year earlier, and net income of $1.62B (7.15 diluted EPS). In FY 2025 it generated $12.64B of operating cash flow and spent $10.07B on buybacks and $679.0M on dividends. As of 2026-03-31, cash was $940.0M against $44.37B of debt.
- Cash
- $940.0M
- Debt
- $44.37B
- Equity
- -$6.30B
- Total assets
- $61.45B
- Shares outstanding
- 221,839,800
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q1 FY 2026 | 2026-03-31 | $19.11B | $1.62B | 8.5% | 7.15 |
| Q4 FY 2025derived | 2025-12-31 | $19.51B | $1.88B | 9.6% | n/a |
| Q3 FY 2025 | 2025-09-30 | $19.16B | $1.64B | 8.6% | 6.96 |
| Q2 FY 2025 | 2025-06-30 | $18.61B | $1.65B | 8.9% | 6.83 |
| Q1 FY 2025 | 2025-03-31 | $18.32B | $1.61B | 8.8% | 6.45 |
| Q4 FY 2024derived | 2024-12-31 | $18.29B | $1.44B | 7.9% | n/a |
| Q3 FY 2024 | 2024-09-30 | $17.49B | $1.27B | 7.3% | 4.88 |
| Q2 FY 2024 | 2024-06-30 | $17.49B | $1.46B | 8.4% | 5.53 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $75.60B | $6.78B | $12.64B | $4.94B | $10.07B | $679.0M |
| FY 2024 | 2024-12-31 | $70.60B | $5.76B | $10.51B | $4.88B | $6.04B | $690.0M |
| FY 2023 | 2023-12-31 | $64.97B | $5.24B | $9.43B | $4.74B | $3.81B | $661.0M |
| FY 2022 | 2022-12-31 | $60.23B | $5.64B | $8.52B | $4.39B | $7.00B | $653.0M |
| FY 2021 | 2021-12-31 | $58.75B | $6.96B | $8.96B | $3.58B | $8.21B | $624.0M |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-03-31; shares outstanding as of 2026-04-27 from the cover page.
What this page is
HCA Healthcare in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows HCA Healthcare (HCA), SEC CIK 860730, listed on NYSE, classified by the SEC as services-general medical & surgical hospitals, nec. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-28.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-24.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-02-18.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-04-30.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-03-31.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-10-27.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-08-26.JSON and CSV
- Company record
- EDGAR filing index for CIK 860730Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as services-general medical & surgical hospitals, nec
Other company pages
- AESAES
- AFLAflac
- AFRMAffirm Holdings
- AGFirst Majestic Silver
- AGCOAGCO
- AGIAlamos Gold
- AGNCAGNC Investment
- AGXArgan
- AHRAmerican Healthcare REIT
- AIGAmerican International Group
- AJGArthur J. Gallagher
- AKAMAkamai Technologies
- ALABAstera Labs
- ALBAlbemarle
- ALGNAlign Technology
- ALHCAlignment Healthcare
- ALLAllstate
- ALLEAllegion
- ALLYAlly Financial
Datasets
Frequently Asked Questions
How much of HCA is sold short?
4,906,014 shares were held short at the 2026-10-15 settlement, 4.6 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is HCA's daily short volume?
On 2026-10-28, 296,642 of the 776,545 HCA shares reported to FINRA were sold short, 38.2% of the day's reported volume. Short volume is a flow for one day, not a position.
Does HCA have fails to deliver?
The SEC's latest file shows 491 HCA shares failed to deliver at settlement 2026-09-24. Fails are reported per settlement date and published twice a month with a lag.
Are HCA insiders buying or selling?
No open-market insider trades were reported for HCA in the last 90 days. The most recent filings are listed below. Latest filing: McAlevey Michael R (EVP & Chief Legal & Admin Off.) on 2026-08-26.
Have HCA insiders filed to sell?
5 Form 144 notices on file for HCA worth $29.1M at the prices reported; 0 in the last 90 days worth $0. Latest: Michael R McAlevey filed on 2026-02-18 to sell 1,694 shares ($903K) from 2026-02-18.
Who owns 5% or more of HCA?
7 holders report 5% or more of HCA in their latest filing, 6 on Schedule 13D (active intent). The largest reported stake is Thomas F. Frist, Jr. at 31.6% of the class (70,555,590 shares), filed 2026-02-10 for an event on 2026-02-06.
What did HCA report last quarter?
In Q1 FY 2026 (quarter ended 2026-03-31) HCA Healthcare reported revenue of $19.11B, up 4.3% from the same quarter a year earlier, and net income of $1.62B (7.15 diluted EPS). In FY 2025 it generated $12.64B of operating cash flow and spent $10.07B on buybacks and $679.0M on dividends. As of 2026-03-31, cash was $940.0M against $44.37B of debt.
Which tracked 13F managers own HCA?
7 of the 30 tracked 13F managers held HCA shares at their latest filing, $326.5M in all. The largest: Cliff Asness's AQR Capital Management (225K shares, $87.6M), Ray Dalio's Bridgewater Associates (203K shares, $79.2M), Ken Griffin's Citadel Advisors (184K shares, $71.9M), D. E. Shaw & Co. (139K shares, $54.4M), Izzy Englander's Millennium Management (64K shares, $24.9M), Renaissance Technologies (19K shares, $7.3M). The table above lists all 7.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.